[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metastasis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metastasis":29},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,43,75,101,130,171,199,222,253,284,309,342,366,390,418,445,466,494,521,544,567,588,604,628,657],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100582435","phase-1-a-clinical-study-of-ifinatamab-deruxtecan-based-treatment-combinations-or-as-monotherapy-to-treat-metastatic-castrate-resistant-prostate-cancer-mcrpc-mk-2400-01aideate-prostate02-100582435",false,"NCT06863272","A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A\u002FIDeate-Prostate02)","MK-2400-01A Substudy: A Phase 1\u002F2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology\n* Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months before Screening\n* Has current evidence of metastatic disease\n* Has received prior treatment with 1 or 2 androgen receptor pathway inhibitors (ARPIs) and progressed during or after treatment\n* Participants receiving bone resorptive therapy (including, but not limited to bisphosphonate or denosumab) must have been on stable doses for ≥4 weeks before allocation\u002Frandomization\n* An Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 assessed within 10 days before allocation\u002Frandomization\n* Has prior treatment with poly-ADP-ribose polymerase inhibitors (PARPi) if indicated by local approved regimen or were deemed ineligible to receive PARPi by the investigator\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* History of (non-infectious) interstitial lung disease (ILD)\u002Fpneumonitis that required steroids, or has current ILD\u002Fpneumonitis or suspected ILD\u002Fpneumonitis\n* Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses\n* Uncontrolled or significant cardiovascular disease\n* History of pituitary dysfunction\n* Poorly controlled diabetes mellitus\n* History or current condition of adrenal insufficiency (eg, Addison's disease)\n* Has received prior treatment with taxane-based chemotherapy agent for metastatic castration-resistant prostate cancer (mCRPC).\n* Chronic steroid treatment (dose of \\>10 mg daily prednisone equivalent), except for low-dose inhaled steroids (for asthma\u002Fchronic obstructive pulmonary disease), topical steroids (for mild skin conditions), or intra-articular steroid injections\n* Received prior radiotherapy within 2 weeks of start of study intervention, or has radiation-related toxicities, requiring corticosteroids\n* Known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Active autoimmune disease that has required systemic treatment in the past 2 years\n* History of allogeneic tissue\u002Fsolid organ transplant","ALL","18 Years",{"count":20,"type":21},360,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","The purpose of this substudy is to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd), given alone or with other treatments in participants with metastatic castration-resistant prostate cancer (mCRPC). The goals of this study are to learn about:\n\n* The safety of the study treatment and if people tolerate it.\n* A safe dose level of I-DXd that can be used with other treatments.\n* Participant levels of prostate specific antigen (PSA) during treatment.",[28,29],"Castration-Resistant Prostatic Cancer","Metastasis","RECRUITING","2026-06-30",{"date":33,"type":34},"2026-07-02","ACTUAL",{"date":36,"type":34},"2025-07-03",{"date":38,"type":21},"2031-04-01",{"name":40,"class":41},"Merck Sharp & Dohme LLC","INDUSTRY",82,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":74},"100570861","early-phase-1-feasibility-study-of-personalized-ultra-fractionated-stereotactic-ablative-radiotherapy-pulsar-for-cancers-of-the-central-lung-100570861","NCT06712745","Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung","Inclusion Criteria:\n\n1. Age ≥ 18 years of age.\n2. Histologically proven diagnosis of cancer. At a minimum, the lung tumor in consideration for treatment must be clinically judged as related to the biopsied site.\n3. Stage: Tumor (ITV) 1.5 - 5 cm in maximum diameter.\n4. Tumor entirely within the 2 cm \"central zone\" or within 1 cm of the mediastinum, esophagus or proximal bronchial tree by investigator assessment.\n5. Zubrod\u002FECOG Performance Status 0-2 within 30 days prior to registration.\n6. Ability to tolerate MRI.\n7. All men, as well as women of child-bearing potential\\* must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) from the time of consent, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n\nNote: A female of child-bearing potential is any woman (regardless of sexual orientation, marital status, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n* Has not undergone a hysterectomy or bilateral oophorectomy; or\n* Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n\nExclusion Criteria:\n\n1. Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields.\n2. Plans for the patient to receive other local therapy in lung (including standard fractionated radiotherapy and\u002For surgery) while on this study, except at disease progression.\n3. Females of reproductive potential who are not using an effective method of birth control and females who are pregnant or breastfeeding or have a positive (urine or serum) pregnancy test prior to study entry.\n4. Prior administration of anti-VEGF (vascular endothelial growth factor) therapy within 1 year.",{"count":50,"type":21},30,[52],"EARLY_PHASE1","The objective of this study is to enhance the safety profile of SAbR in ultra-central tumors of the lung (primary or metastatic) without compromising its effectiveness.",[55,29],"Cancer, Lung",[57,58,59,60,61,62,63],"lung","central lumg","cancer","metastasis","PULSAR","non small cell lung cancer","NSCLC","2026-06-24",{"date":66,"type":34},"2026-06-29",{"date":68,"type":34},"2025-09-19",{"date":70,"type":21},"2028-12-30",{"name":72,"class":73},"University of Texas Southwestern Medical Center","OTHER",1,{"id":76,"slug":77,"hasResults":12,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":74},"100636199","phase-2-a-phase-2-study-of-luvometinib-combined-with-anlotinib-in-kras-mutated-nsclc-100636199","NCT07562581","A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC","A Multicenter, Open-label, Single-arm Phase 2 Study to Evaluate the Efficacy and Safety of Luvometinib Combined With Anlotinib in Patients With KRAS-mutated Metastatic Non-small Cell Lung Cancer","Inclusion Criteria\n\n1. aged between ≥ 18 years and ≤75 years; regardless of male or female.\n2. Histologically and\u002For cytologically confirmed diagnosis of non-small cell lung caner,and the clinical stage is IV(AJCC 4th）; Received at least one line of systemic treatment(including platinum-based chemotherapy ± PD-(L)1) during the stage IV, and disease progression occured during or after the treatment.\n3. KRAS mutation positive.\n4. ECOG score 0-1. 5. Expected survival time ≥ 3 months.\n\n6．At least one intracranial measurable lesion according to RECIST v1.1 criteria.\n\n7．Adequate organ function within 7 days before enrollment. 8. Recovery to ≤grade 1 or return to baseline from previous treatment-related adverse events (according to CTCAE 5.0), except for adverse events such as hair loss that are judged by the investigators to be safe and do not violate other inclusion criteria.\n\n9\\. Avoid excessive exposure to sunlight, and be willing to use sufficient sunscreen when there is expected to be sunlight exposure.\n\n10\\. Take contraceptive measures as required.\n\nExclusion Criteria\n\n1．Patients who have previously received any of the following treatments:\n\n1. Prior treatment with MEK inhibitors、anlotinib or other VEGFR-TKI(such as cabozantinib, sorafenib, apatinib,etc);\n2. Major surgery within 28 days or minor surgery within 14 days prior to the first dose, or need to undergo major surgery during the study treatment;\n3. Systemic anti-cancer treatment (including chemotherapy, targeted therapy, immunotherapy, and other clinical trial drug treatments) within 28 days prior to the first dose or within 5 drug half-lives (whichever is shorter).\n4. Treatment with traditional Chinese medicine, Chinese patent medicine or modern Chinese medicine preparations with anti-tumor indications within 7 days prior to the first dose;\n5. Radical radiotherapy within 28 days prior to the first dose; palliative radiotherapy allowed if ≥14 days before first dose;\n6. Live or live-attenuated vaccine within 28 days prior to the first dose; other vaccines (e.g., inactivated COVID-19 vaccine) within 14 days prior to the first dose;\n7. History of allogeneic organ transplantation or allogeneic stem cell transplantation, or autologous stem cell transplantation within 3 months prior to the first dose.\n\n   2．Active CNS metastases; brainstem, leptomeningeal, spinal cord metastases or spinal cord compression.\n\n   3.Small cell lung cancer (including mixed SCLC\u002FNSCLC) or cavitary central squamous cell carcinoma.\n\n   4.Receipt of ≥4 prior lines of systemic anticancer therapy. 5.Active autoimmune disease requiring systemic therapy in the past 2 years,except: stable disease on replacement therapy without systemic treatment; non-systemic dermatologic conditions (vitiligo, psoriasis) or alopecia.\n\n   6.Active infection requiring systemic therapy within 2 weeks before first dose. 7.Uncontrolled hypertension. 8.Dysphagia, active gastrointestinal disease, malabsorption, or any condition impairing study drug absorption.\n\n   9.Retinal vein occlusion (RVO), retinal pigment epithelial detachment (RPED), uncontrolled glaucoma, or other ocular disease interfering with ocular toxicity assessment.\n\n   10.Current or previous idiopathic pulmonary fibrosis\u002Fpneumonitis; active ILD, pneumonitis (including clinically significant radiation pneumonitis), pulmonary fibrosis; history of tracheal fistula; continuous oxygen requirement due to severe dyspnea or respiratory insufficiency.\n\n   11.Active HBV or HCV; known AIDS or positive HIV; active tuberculosis or syphilis.\n\n   12.Tumor invasion into major vessels, heart, pericardium, trachea, esophagus, or high risk of esophagotracheal\u002Fesophagopleural fistula.\n\n   13.Significant hemoptysis within 1 month before first dose; clinically significant bleeding, bleeding tendency, coagulopathy, or history of ≥Grade 3 thrombosis.\n\n   14.Symptomatic or recurrent pleural effusion, ascites, or pericardial effusion requiring frequent drainage.\n\n   15.Other malignancy diagnosed within 5 years before first dose.","75 Years",{"count":84,"type":21},48,[25],"Aim to evaluate the efficacy and safety of luvometinib combined with anlotinib in patients with KRAS-mutated non-small cell lung caner",[88,89,29,90],"Non-small Cell Lung Caner","KRAS-mutated","Previous Treamted","NOT_YET_RECRUITING","2026-04-25",{"date":94,"type":34},"2026-05-01",{"date":96,"type":21},"2026-06",{"date":98,"type":21},"2030-06",{"name":100,"class":41},"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.",{"id":102,"slug":103,"hasResults":12,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":108,"targetDuration":4,"studyType":22,"phases":110,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":74},"100634305","surgery-plus-systemic-therapy-for-liver-cancer-with-extrahepatic-metastases-100634305","NCT07537959","Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases","Primary Tumor Resection Plus Systemic Therapy Versus Systemic Therapy Alone in Hepatocellular Carcinoma With Extrahepatic Metastases: A Multicenter Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n* Age 18 to 75 years\n* Hepatocellular carcinoma confirmed by imaging and\u002For histology according to AASLD or EASL criteria\n* Resectable primary intrahepatic tumor with expected R0 resection\n* ECOG performance status 0 to 1\n* At least one measurable extrahepatic metastatic lesion according to RECIST version 1.1\n* Child-Pugh class A or stable Child-Pugh B7\n* Written informed consent and willingness to comply with study follow-up and data collection\n\nExclusion Criteria:\n\n* Prior systemic therapy for hepatocellular carcinoma, including immunotherapy, targeted therapy, or chemotherapy\n* Decompensated or clinically unstable liver disease, including refractory ascites, recurrent hepatic encephalopathy, active gastrointestinal bleeding, or - Child-Pugh class greater than B7\n* Major bleeding risk or clinically significant coagulation abnormality, including recent gastrointestinal bleeding or untreated\u002Fhigh-risk gastroesophageal varices\n* Active autoimmune disease or long-term systemic immunosuppressive therapy\n* Active severe infection, including uncontrolled bacterial or fungal infection, uncontrolled hepatitis B virus replication without appropriate antiviral treatment, or active tuberculosis\n* Uncontrolled central nervous system metastases\n* Uncontrolled cardiovascular disease, including poorly controlled hypertension, recent myocardial infarction, unstable angina, stroke, or major thrombotic event\n* Significant proteinuria or renal dysfunction considered unsuitable for study treatment\n* Another active malignancy, except for selected low-risk malignancies allowed by the investigator and ethics committee\n* Pregnancy or breastfeeding\n* Known severe hypersensitivity to study-related drugs\n* Poor compliance, psychiatric or cognitive disorder preventing study participation, or any other condition judged by the investigator to make the participant unsuitable for the trial",{"count":109,"type":21},280,[111],"NA","This study will evaluate whether resection of the primary liver tumor, in addition to standard first-line systemic therapy, improves survival in patients with hepatocellular carcinoma that has spread outside the liver but still has a resectable primary intrahepatic tumor. Participants will be randomly assigned to receive either primary tumor resection followed by protocol-allowed first-line immune-based systemic therapy or systemic therapy alone. The primary outcome is overall survival. Secondary outcomes include progression-free survival, objective response rate, disease control rate, immune-related adverse events, postoperative complications, and quality of life.",[114,29],"Hepatocellular Carcinoma (HCC)",[116,117,118,119,120],"Hepatocellular Carcinoma","Extrahepatic Metastases","Primary Tumor Resection","Systemic Therapy","Immunotherapy","2026-04-12",{"date":123,"type":34},"2026-04-17",{"date":125,"type":21},"2026-04-30",{"date":127,"type":21},"2031-04-30",{"name":129,"class":73},"Tongji Hospital",{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":157,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":170},"100543937","phase-1-a-study-of-oral-7hp349-alintegimod-in-combination-with-ipilimumab-followed-by-nivolumab-monotherapy-100543937","NCT06362369","A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","A Phase 1b\u002F2a Multi-Center, Dose Escalation and Reference Regimen-Controlled, Multi-Cohort Study to Determine the Safety and Efficacy of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy in Patients With Locally Advanced or Metastatic Cancers Following One or More Prior Therapies","Inclusion and Exclusion Criteria for Phase 1b\n\nInclusion Criteria\n\n1. Adult patients (age 18 or older)\n2. Patient has a histologically confirmed diagnosis of any of the following locally advanced or metastatic solid tumors: melanoma, pleural mesothelioma, renal cell carcinoma, MSI-high or mismatch repair-deficient colorectal cancer, hepatocellular carcinoma, and non-small cell lung cancer with no EGFR or anaplastic lymphoma kinase (ALK) genomic tumor aberrations, or tumor types for which the combination of ipilimumab and nivolumab has been FDA approved. Patients may have received treatment with anti PD-1\u002FPD-L1.\n3. ANC ≥ 1000\u002FµL without use of G-CSF, Hgb ≥ 9 g\u002FdL without required blood transfusion for at least 5 days prior to pretreatment baseline, and platelet count ≥ 75,000\u002FµL without transfusions for at least 5 days prior to pretreatment baseline.\n4. ECOG performance status of 0 or 1.\n5. Has a life expectancy of \\> 12 weeks.\n6. Renal and hepatic function requirements:\n\n   * a. Renal function with either an eCrCL ≥ 60 mL\u002Fmin (modified Cockcroft-Gault) or eGFR ≥ 60 mL\u002Fmin\u002F1.73 m2 (using MDRD or CKD-EPI or similar equations).\n   * b. Hepatic function with ALT\u002FAST ≤ 3 x ULN, total bilirubin ≤ 1.5 x ULN (except for patients with Gilbert Syndrome). If patients have hepatic metastases, then AST\u002FALT≤ 5 x ULN will be allowed.\n7. Men receiving the investigational drug and are sexually active with women of child-bearing potential (WCBP) must use contraception during treatment and for 5 half-lives after the last dose of the investigational drug or Women, not otherwise meeting other exclusion criteria, who are WCBP must be on contraception for a minimum duration of 3 months prior to treatment and continue contraception during treatment and for 5 half-lives after the last dose of the investigational drug.\n8. All Grade 3 AEs related to prior therapies have returned to Grade 1 or resolved to baseline (this includes with appropriate therapy in the case of thyroid dysfunction).\n9. All patients must have measurable disease by applicable RECIST criteria.\n10. Willing to allow blood samples to be used for research.\n\nExclusion Criteria:\n\n1. Patients must not have received prior anticancer therapy or radiation therapy within the 3 weeks and must not have undergone major surgery within 4 weeks prior to initiation of treatment on protocol. Palliative radiation therapy is allowed. For small molecules (MW \\\u003C 0.9 kDA), the washout period is 3 weeks or 5 half-lives, whatever comes first.\n2. Active brain metastasis or leptomeningeal disease. Patients with treated brain metastasis must have stable disease, evidenced by MRI brain imaging for at least 4 weeks, and the patient must have been off steroids for at least 2 weeks prior to first dose of study drug.\n3. Previous episodes of ≥ Grade 3 (G3) immune-related toxicity that includes G3 colitis, G3 pneumonitis, G3 skin rash, G3 increase in liver enzymes (with the exception of symptoms that in the opinion of the investigator will not compromise the patients' safety on the trial. Patients with stable endocrinological AEs (e.g., hypothyroidism, adrenal insufficiency, hypopituitarism, or diabetes mellitus) are allowed.\n4. Persistent toxicity of NCI CTCAE version 5 Grade \\> 1 severity that is related to prior therapy.\n\n   Note: Sensory neuropathy, hypothyroidism or alopecia of Grade ≤ 2 are acceptable. Other Grade 2 toxicities of prior treatments that are controlled with medication (e.g., diabetes or hypertension) are permitted.\n5. Concurrent administration of medications or foods that are strong inhibitors or inducers of cytochrome p450 3A (CYP3A) within 2 weeks before study intervention. Alintegimod may increase exposure to CYP3A4 substrates; consider a dose reduction of such substrates and monitor for signs of toxicities of co-administered sensitive CYP3A substrates (see listing of strong inhibitors and inducer drugs in FDA tables). An alternative is to replace such agents with drugs that are not CYP3A4 metabolized if at all feasible.\n6. The patient has cardiac conditions as follows:\n\n   * a) myocarditis;\n   * b) uncontrolled hypertension (blood pressure \\> 160\u002F100) despite optimal therapy;\n   * c) uncontrolled angina; ventricular arrhythmias; congestive heart failure (New York Heart Association Class II or above);\n   * d) prior or current cardiomyopathy;\n   * e) uncontrolled atrial fibrillation with heart rate \\> 100 beats per minute (bpm); unstable ischemic heart disease (myocardial infarction within 6 months prior to starting treatment or angina requiring use of nitrates more than once weekly);\n   * f) concomitant medication with drugs known to cause Torsades de Pointes;87\n   * g) QT interval correction for heart rate using Fridericia's formula (QTcF) ≥ 470 ms (average from 3 QTcF values on the triplicate 12-lead electrocardiogram \\[ECG\\]) at screening.\n7. Known history of a positive test for HIV, or positive test for hepatitis B (positive for HBsAg) or hepatitis C (HCV RNA).\n8. Concurrent malignancies are permitted if they were previously treated, and all treatment of that malignancy was completed at least 2 years before enrollment and no evidence of disease exists, or with agreement from the Principal Investigator (PI), patients who have a concurrent malignancy that is clinically stable and does not require tumor-directed treatment are eligible to participate if the risk of the prior malignancy interfering with either safety or efficacy endpoints is very low, or with agreement from the PI, other malignancies may be permitted if the risk of the prior malignancy interfering with either safety or efficacy end points is very low. Adequately treated basal or squamous cell carcinoma or carcinoma in situ is allowed.\n9. Men receiving the investigational drug and are sexually active with women of child-bearing potential (WOCBP) must use contraception during treatment and for 5 half-lives after the last dose of the investigational drug or Women, not otherwise meeting other exclusion criteria, who are WOCBP must be on contraception for a minimum duration of 3 months prior to treatment and continue contraception during treatment and for 5 half-lives after the last dose of the investigational drug.\n10. The patient has concurrent severe and\u002For uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes, severe infection requiring active treatment, severe malnutrition, chronic severe liver or renal disease).\n11. Use of corticosteroids or other immunosuppressive medication, current or within 14 days of administration of Alintegimod with the following exceptions:\n\n    * a) Topical, intranasal, inhaled, ocular, intra-articular corticosteroids;\n    * b) Physiological doses of replacement corticosteroids (e.g., for adrenal insufficiency) are not to exceed 10 mg\u002Fday of prednisone or equivalent.\n    * c) Corticosteroid premedication for infusion and\u002For hypersensitivity reactions.\n    * d) Patients may be treated with a short (\\\u003C24h) pulse course of corticosteroids to mitigate infusion or hypersensitivity reactions to radiocontrast agents.\n12. Receipt of live attenuated vaccine within 28 days of the first dose of Alintegimod.\n13. Serious autoimmune disease at the discretion of the treating Investigator: patients with a history of active serious inflammatory bowel disease (including Crohn's disease and ulcerative colitis) and autoimmune disorders such as rheumatoid arthritis, systemic progressive sclerosis (scleroderma), systemic lupus erythematosus or autoimmune vasculitis (e.g., Wegener's Granulomatosis) are excluded from participation in this study\n14. Active or history of pneumonitis (drug-induced), idiopathic pulmonary fibrosis, Interstitial Lung Disease (ILD), or lung disease that may interfere with assessment of pneumonitis. History of radiation pneumonitis in a previous radiation field is permitted.\n15. Previous participation in a study of any investigational agent within 21 days of enrollment or within 5 half-lives of the study treatment, whichever is the least.\n16. Use of mechanical ventilation or having a resting O2 saturation \\\u003C 90% (on room air) by pulse-oximetry, require renal dialysis, require vasopressors, and\u002For severe hepatic sinusoidal obstruction syndrome.\n17. Proven or suspected ongoing systemic infection requiring IV antibiotics.\n18. Women who are pregnant or lactating.\n\n    Note: Women of childbearing potential (WOCBP) must have a \"negative\" serum pregnancy test within 1 week prior to treatment. Non-childbearing potential is defined as 1 of the following:\n    * a) Postmenopausal with \\> 1 year since last menses and:\n    * 1\\. If ≥ 65 years old, follicle-stimulating hormone (FSH) \\> 40 mIU\u002FmL.\n    * 2\\. If ≥ 65 years old and not on hormone replacement therapy (HRT), FSH \\> 30 mIU\u002FmL.\n    * 3\\. If ≥ 65 years old and on HRT, the FSH requirement is not applicable. Postmenopausal females on HRT will be allowed if HRT has been stable for ≥ 6 months prior to dosing of study drug(s).\n    * b) Written medical documentation of being sterilized (e.g., hysterectomy, double oophorectomy, bilateral salpingectomy) with the procedure performed ≥ 6 months prior to dosing study drug(s).\n\n    Note: Tubal ligation is not considered a form of permanent sterilization.\n19. Psychiatric illness\u002Fsocial circumstances that would limit compliance with study requirements and substantially increase the risk of adverse events or have compromised ability to provide written informed consent.\n20. Patients who have had allogeneic tissue or solid organ transplantation. Prior T cell therapy is allowed\n21. Use of biotin (i.e., Vitamin B7) or supplements containing biotin higher than the daily adequate intake of 30 µg (NIH-ODS 2022; Section 5.9.2.1).\n\n    Note: Patients who switch from a high dose to a dose of ≤30 µg\u002Fday are eligible for study entry.\n22. Any condition that is in the opinion of the investigator may compromise patient's participation in the trial.\n23. Active peptic ulcer disease or gastritis, active diverticulitis, or other serious gastrointestinal disease associated with diarrhea within the past 2 years before the start of therapy or GI disease which affects oral drug absorption.\n24. Patients with known soy allergy.",{"count":138,"type":21},126,[24,25],"This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.\n\nCurrently study will only be enrolling the Phase 1b and the Phase 2a protocol requirements will be added to the study near completion of the Phase 1b",[142,143,144,29,145,146,147,148,149,116,150,151,152,153,154,63,155,156],"Advanced Cancer","Advanced Solid Tumor","Melanoma","Pleural Mesothelioma","Renal Cell Carcinoma","MSI-High","Mismatch Repair Deficiency","Colorectal Cancer","Hepatocellular Cancer","Renal Cell Cancer","Kidney Cancer","Skin Cancer","Non Small Cell Lung Cancer","Anaplastic Lymphoma Kinase Genomic Tumor Aberrations","ALK Genomic Tumor Aberrations",[158,159,160],"Phase 1","Phase 1b","7 Hills Pharma","2026-04-07",{"date":163,"type":34},"2026-04-13",{"date":165,"type":34},"2024-08-23",{"date":167,"type":21},"2028-12-31",{"name":169,"class":41},"7 Hills Pharma, LLC",5,{"id":172,"slug":173,"hasResults":12,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":4,"eligibilityCriteria":177,"healthyVolunteers":178,"sex":17,"minAge":18,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":191,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":198},"100446574","phase-1-abemaciclib-in-combination-with-bicalutamide-for-androgen-receptor-positive-her2-negative-metastatic-breast-cancer-100446574","NCT05095207","Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer","A Multicenter, Phase IB\u002FII Study of Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer","Inclusion Criteria:\n\n* Provision of signed and dated, written informed consent prior to any study specific procedures, sampling and analyses\n\n  * If a patient declines to participate in any voluntary exploratory research and\u002For genetic component of the study, there will be no penalty or loss of benefit to the patient and he\u002Fshe will not be excluded from other aspects of the study\n* Women aged at least 18 years\n* The patient has a biopsy-confirmed diagnosis of recurrent, unresectable, locally advanced, or metastatic HER2neu-negative breast cancer (including bone-only metastatic disease) o The patient must have had biopsy confirmation of a metastatic site (with appropriate ER\u002FPR\u002FHER2neu IHC staining)\n\n  o The patient has measurable or evaluable disease as evidenced on pre-treatment baseline CT chest, abdomen, and pelvis with bone scan OR PET\u002FCT\n* The patient has AR+ breast cancer (defined as \\> or equal to 1% staining on immunohistochemistry of metastatic breast cancer specimen)\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2 with no deterioration over the previous 2 weeks and minimum life expectancy of 12 weeks\n* If the patient has ER+ or PR+ (\\>1% on IHC) metastatic breast cancer:\n\n  o patient must have had 1 prior line of endocrine therapy in the metastatic setting\n  * prior CDK4\u002F6 inhibitor exposure allowed (abemaciclib. palbociclib, or ribociclib)\n  * no more than 2 prior line of cytotoxic chemotherapy in the metastatic setting allowed\n* If the patient has ER-,PR-, HER2- metastatic breast cancer (\"triple-negative\"):\n\n  o The patient may have had up to 4 prior lines of chemotherapy in the metastatic setting and at least 1 prior line of chemotherapy in the metastatic setting\n* Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events \\[CTCAE\\] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at least 21 days is required between last chemotherapy dose and randomization (provided the patient did not receive radiotherapy).\n* Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization.\n* Post-menopausal status or receiving ovarian ablation with a GnRH agonist such as goserelin or leuprolide. Postmenopausal status is defined by any one of the following criteria:\n\n  * Prior bilateral oophorectomy.\n  * Age ≥ 60 years.\n  * Age \\\u003C 60 and amenorrhea for 12 or more months (in the absence of chemotherapy, tamoxifen, or ovarian suppression) and FSH, LH, and estradiol in the postmenopausal range per local normal.\n\nIf the patient does not meet criteria for postmenopausal status but is receiving ovarian ablation therapy with a gonadotropin-releasing hormone (GnRH) agonist such as goserelin or leuprolide, the patient is eligible for the study, provided that the GnRH agonist is started at least 2 weeks prior to C1D1 of study therapy.\n\n\\- Negative serum pregnancy test within 7 days prior to starting treatment\n\n• Women of child-bearing potential and men must agree to use a highly effective method of contraception prior to study entry, for the duration of study participation, and for 3 weeks following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately, as cases of pregnancy that occur during maternal exposures to abemaciclib should be reported. If a patient or spouse\u002Fpartner is determined to be pregnant following abemaciclib initiation, she must discontinue treatment immediately. Data on fetal outcome and breast-feeding are to be collected for regulatory reporting and drug safety evaluation.\n\nNote: Recommended methods of birth control are: The consistent use of an intrauterine device (IUD), Double barrier methods (Diaphragm with spermicidal gel or condoms with contraceptive foam), Sexual abstinence (no sexual intercourse) or Sterilization.\n\nMen must agree to use a condom and not father a child or donate sperm for the duration of the study and for 90 days after completion of therapy.\n\nA female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n* Has not undergone a hysterectomy or bilateral oophorectomy; or\n* Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n\nExclusion Criteria:\n\n* Treatment with any of the following:\n\n  1. Any investigational agents or study drugs from a previous clinical study within 28 days of the first dose of study treatment\n  2. Any other chemotherapy, immunotherapy or anticancer agents within 21 days of the first dose of study treatment\n  3. Any prior exposure to anti-androgen therapy (bicalutamide, abiraterone, and\u002For enzalutamide)\n* Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment\n* Spinal cord compression, leptomeningeal carcinomatosis, or brain metastases - unless asymptomatic, treated and stable and not requiring steroids for at least 2 weeks prior to start of study treatment\n* Concurrent use of endocrine therapy (tamoxifen, anastrozole, letrozole, exemestane, oral contraceptive pills)\n* As judged by the investigator, any evidence of severe or uncontrolled systemic diseases, including active bleeding diatheses, or active infection including hepatitis B, hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions is not required.\n* Any of the following cardiac criteria:\n\n  1. Mean resting corrected QT interval (QTc) \\> 470 msec obtained from 3 consecutive electrocardiograms (ECGs)\n  2. Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG (e.g., complete left bundle branch block, third degree heart block)\n  3. Any factors that increase the risk of QTc prolongation or risk of arrhythmic events such as heart failure, abnormalities in serum electrolytes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age or any concomitant medication known to prolong the QT interval\n  4. Personal history of syncope of cardiovascular etiology, ventricular arrhythmia (of pathologic origin including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.\n  5. Experience of any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure NYHA Grade 2 or greater\n  6. Uncontrolled hypotension - Systolic BP \\\u003C90mmHg and\u002For diastolic BP \\\u003C50mmHg\n  7. Left ventricular ejection fraction (LVEF) below lower limit of normal for site\n* Prior history of DVT\u002FPE or embolic stroke, unless currently on therapeutic anticoagulation\n* Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:\n\n  1. Absolute neutrophil count \\\u003C 1.5 x 109\u002FL\n  2. Platelet count \\\u003C 100 x 109\u002FL\n  3. Hemoglobin \\\u003C 8 g\u002FL (Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.)\n  4. Alanine aminotransferase \\> 3 times the upper limit of normal (ULN)\n  5. Aspartate aminotransferase \\> 3 times ULN\n  6. Total bilirubin \\> 1.5 times ULN (patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted)\n  7. Creatinine \\>1.5 times ULN concurrent with creatinine clearance \\\u003C 50 ml\u002Fmin (measured or calculated by Cockcroft and Gault equation); confirmation of creatinine clearance is only required when creatinine is \\> 1.5 times ULN\n  8. Proteinuria 3+ on dipstick analysis or \\>500mg\u002F24 hours\n  9. Sodium or potassium outside normal reference range for site\n* Liver disease such as cirrhosis, chronic active hepatitis, or chronic persistent hepatitis. Patients who are hepatitis B Core antibody IgG positive are allowed to participate if taking and compliant with daily oral hepatitis B prophylactic medications\n* The patient has serious and\u002For uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \\[e.g. estimated creatinine clearance \\\u003C30ml\u002Fmin\\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).\n* Severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and\u002For 02 saturation that is 89% or less at rest on room air\n* Uncontrolled diabetes as defined by fasting serum glucose \\>1.5 x ULN\n* Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product, or previous significant bowel resection that would preclude adequate absorption abemaciclib or bicalutamide\n* Patients with an active bleeding diathesis\n* The patient has active systemic bacterial infection (requiring intravenous \\[IV\\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \\[for example, hepatitis B surface antigen positive\\]. Screening is not required for enrollment.\n* History of hypersensitivity or allergic reaction to abemaciclib or bicalutamide, or drugs with a similar chemical structure or class\n* Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements\n* Co-administration with CYP3A4 inducers (e.g., phenytoin, rifampin, carbamazepine, St John's Wort, bosentan, efavirenz, etravirine, modafinil, and nafcillin), CYP3A4 inhibitors (e.g., clarithromycin, indinavir, itraconazole, ketoconazole, lopinavir\u002Fritonavir, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, verapamil, and voriconazole), and CYP3A4 substrates (e.g., alfentanil, cyclosporine, dihydroergotamine, ergotamine, everolimus, fentanyl, pimozide, quinidine, sirolimus and tacrolimus). See Appendix C for complete list.\n* Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.\n* Female patients who are pregnant or breast feeding\u002Flactating, or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Hormonal contraceptives are not acceptable as a method of contraception.",true,"90 Years",{"count":181,"type":21},42,[24,25],"This is an open label multicenter, Phase IB\u002FII Study of Abemaciclib in Combination with Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer",[185,29],"Breast Cancer",[185,187,188,189,190],"Androgen Receptor-positive","HER2 negative","Abemaciclib","Bicalutamide",{"date":163,"type":34},{"date":193,"type":34},"2021-09-20",{"date":195,"type":21},"2028-06",{"name":197,"class":73},"Icahn School of Medicine at Mount Sinai",3,{"id":200,"slug":201,"hasResults":12,"nctId":202,"briefTitle":203,"officialTitle":204,"acronym":205,"eligibilityCriteria":206,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":210,"conditions":211,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":220,"locationsCount":74},"100576570","resection-of-the-primary-tumor-vs-systemic-treatment-alone-for-patients-with-small-intestinal-neuroendocrine-tumors-and-unresectable-metastases-a-europe-wide-study-100576570","NCT06787014","Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Europe-wide Study","Resection of the Primary Tumor vs. Systemic Treatment Alone for Patients With Small Intestinal Neuroendocrine Tumors and Unresectable Metastases: a Retrospective, Europe-wide, Pooled Cohort Study (ENETS-SurgSmInt)","ENETSSurgSmInt","Inclusion Criteria:\n\n\\- All patients with siNET and non-curative metastatic disease between 01.01.2005 and 31.12.2021 will be included.\n\nExclusion Criteria:\n\n\\- All patients with siNET G3, resectable metastatic disease and\u002For non-resectable primary tumor at initial diagnosis will be excluded. Furthermore, symptomatic patients (small intestinal obstruction, bleeding) or when imaging suggests that obstruction will probably occur (bowel dilatation, mesenteric fibrosis) at initial diagnosis will be excluded. Patients with diarrhea, flushing, or abdominal pain will not be excluded.\n\nPatients with a documented rejection for a further use of their data for scientific purposes will also be excluded.",{"count":208,"type":21},3200,"OBSERVATIONAL","When possible, surgery to completely remove small intestinal neuroendocrine tumors (siNETs) is always recommended. However, in cases where the tumor has spread and cannot be cured completely, it is unclear whether a surgical removal of the primary tumor only is reasonable. In this situation, current guidelines from the European Neuroendocrine Tumor Society (ENETS) recommend surgery only for patients who have symptoms like intestinal blockage or bleeding, or are at risk of such complications. For patients without symptoms, it is still unclear whether removing the main tumor improves overall outcomes and prevents future problems.\n\nStudies evaluating this type of surgery on survival show conflicting results. These studies often do not separate patients with symptoms from those without, and they overlook other important factors like the amount of cancer in the liver and nearby tissues. Due to these uncertainties, the rarity of siNETs and many factors that can affect outcomes, like age, overall health, or other current treatments, conducting a high-quality study to answer this question is challenging. To address this, the present Europe-wide study is being planned.\n\nThis study aims to determine if resecting the main tumor improves the 10-year overall survival and reduces risks like intestinal blockages or blood flow issues compared to no surgery in patients without symptoms. The study will also assess other outcomes, such as how long patients stay free from disease progression, the risks of surgery, and prognostic factors for long-term survival. This international collaboration among neuroendocrine tumor referral centers will provide robust evidence to guide clinical practice and update treatment guidelines for siNETs.",[212,29,213],"Neuroendocrine (NE) Tumors","Bowel Obstruction","2026-03-17",{"date":216,"type":34},"2026-03-18",{"date":218,"type":34},"2026-03-09",{"date":167,"type":21},{"name":221,"class":73},"Insel Gruppe AG, University Hospital Bern",{"id":223,"slug":224,"hasResults":12,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":12,"sex":17,"minAge":229,"maxAge":230,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":252},"100629652","phase-2-a-study-of-gefitinib-trametinib-disulfiram-and-sunitinib-in-addition-to-standard-chemotherapy-in-people-with-osteosarcoma-100629652","NCT07477457","A Study of Gefitinib, Trametinib, Disulfiram, and Sunitinib in Addition to Standard Chemotherapy in People With Osteosarcoma","OstEvo - Osteosarcoma Evolves","Inclusion Criteria:\n\nCohort 1 only: Newly Diagnosed, Metastatic Osteosarcoma\n\n1. For study entry, the suspected diagnosis of osteosarcoma may be based on clinical judgement. Biopsy confirmation is required for treatment but as this protocol has biologic aims from serial tumor samples, some patients will be enrolled prior to open biopsy. Patients must have a histologic new diagnosis of metastatic high-risk osteosarcoma to start OstEvo systemic therapy. For purposes of this protocol, newly diagnosed, high-risk metastatic osteosarcoma includes:\n\n   1. Having at least 1 extrapulmonary metastasis, radiographic confirmation of metastasis is adequate, and\u002For\n   2. Unresectable metastases at diagnosis as determined by the investigator\n2. Patients may have started systemic conventional chemotherapy but must enroll on this study prior to day 29 of chemotherapy initiation. Having received a single standard MAP cycle (AP x 1 and HDMTX up to 2 times) of chemotherapy prior to enrollment is acceptable\n\nCohort 2 only: Relapsed, Metastatic Osteosarcoma\n\n1\\. Patients must have achieved a radiographically confirmed complete response as determined by the investigator from initial therapy and then relapsed with metastatic high-risk osteosarcoma. No strict size criteria of pulmonary or additional nodules for eligibility are required. For purposes of this protocol, relapsed, metastatic, high-risk osteosarcoma includes:\n\na. First relapse within 24 months of start of first chemotherapy or b. First relapse involving more than one lung nodule, or the lung and any extrapulmonary sites or c. First relapse with pleural disruption at relapse as determined by the investigator which can be determined by CT scan and\u002For d. Multiply relapsed patients are eligible provided the current relapse is in the context of a radiographically confirmed complete response on the scans preceding the relapse making them potentially eligible for OstEvo 2. Patients may have received only a single cycle of ifosfamide-containing conventional chemotherapy ever and included for the relapse making them eligible for OstEvo, but must enroll on this study prior to day 22 of the first cycle post-relapse\n\nCohort 3 only\n\n1. Patients with newly diagnosed osteosarcoma who are not eligible for Cohorts 1 or 2.\n2. Diagnostic biopsy has insufficient material for research.\n3. Must be enrolled on MSK IRB 12-245, biospecimen research protocol, with oncologic surgeries planned to be performed at MSK.\n4. Orthopedic surgeon assessment is that a research biopsy will not increase the risk of local recurrence.\n5. Patients must be willing to assent, and consenting party must consent to the single research biopsy prior to the initiation of chemotherapy. Patients over 18 must consent to research biopsies at study entry.\n\nCohorts 1 and 2 only\n\n1. Age: Patient must be \\> 6 and \\\u003C 50 years of age at the time of study enrollment.\n2. Disease Status: Metastatic high-risk osteosarcoma with cohort specific criteria above\n3. Performance Level: Karnofsky ≥ 50% for patients \\> 16 years of age and Lansky \\> 50 for patients \\\u003C 16 years of age within 28 days prior to enrollment.\n4. Oral Medications: Patients must be able to swallow oral medications as whole tablets\u002Fcapsule form if a commercially available oral suspension is not available or if tablet dissolution is not stated in the protocol.\n5. Organ Function Requirements:\n\n   1. Adequate Hematologic function, defined as:\n\n   i. Absolute neutrophil count \\> 250 cells\u002FmcL ii. Platelet count \\> 50,000\u002FmcL b. Adequate Renal Function, defined as: i. May use creatinine clearance (estimated or by cystatin C) or radioisotope GFR \\> 70 mL\u002Fmin\u002F1.73m2 or estimated GFR (eGFR) in pediatric patients ii. A serum creatinine based on age\u002Fsex (use the Schwartz formula for estimating GFR) c. Adequate Liver Function, defined as: i. Total bilirubin \\\u003C 1.5 x ULN for age ii. AST and ALT \\\u003C 3 x ULN for age d. Adequate Cardiac Function, defined as: i. No history of congenital prolonged QTc syndrome ii. Correct QT (using Fridericia's correction \\[QTcF\\]) interval \\\u003C 480 msec.\n\n1\\. QTcF = QT \u002F RR(0.33), where RR = 60 \u002F heart rate in bpm iii. Left ventricular ejection fraction (LVEF) \\> 55 % on echocardiogram or MUGA 6. Assent and Consent: Patients at least 7 years old and less than 18 years old must be willing to assent, and consenting party must consent to research biopsies in Cohort 1. Patients 18 years and older must consent to research biopsies at study entry. All patients and\u002For their parents or legal guardians must have the ability to understand and the willingness to sign a written informed consent or assent document.\n\n7\\. Tumor Tissue: Patients must have adequate biopsy tumor tissue, or the patient is willing to undergo a pretreatment research biopsy. A research biopsy following cycles 1 and 2 of treatment done with the thoracotomy procedure will be required. Availability of these paired biopsies will be informative to understanding mechanisms of response and resistance to initial therapy in osteosarcoma and may benefit future patients with this rare cancer.\n\n8\\. Concurrent Study Enrollment: Must be enrolled on MSK IRB 12-245, biospecimen research protocol, with oncologic surgeries planned to be performed at MSK.\n\n9\\. Pregnancy or Breast Feeding: The effects of the chemotherapeutic agents in OstEvo on the developing human fetus are unknown. For this reason and because OstEvo agents as well as other therapeutic agents used in this trial are known to be teratogenic, participants of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) during study therapy and for 12 months following the completion of study therapy. Should a participant become pregnant or suspect pregnancy while participating in this study, they should inform their treating physician immediately.\n\n10\\. Contraception: Women of childbearing potential should adhere to contraception from enrollment through 12 months after completion of systemic chemotherapy administration. Men who are sexually active with women of childbearing potential should adhere to contraception from enrollment through 12 months after completion- of systemic chemotherapy administration 11. Protocol Adherence: Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and evaluations.\n\nExclusion Criteria:\n\nCohorts 1 and 2 only:\n\n1. Patients who are receiving any other investigational agents for osteosarcoma therapy are ineligible.\n2. Patient with an uncontrolled chronic or active infection or another condition where any component of OstEvo therapy would be contraindicated.\n3. Patients with a history of heart disease including, but not limited to: uncontrolled hypertension within 12 months prior to enrollment; ongoing cardiac dysrhythmias ≥ grade 2 or atrial fibrillation of any grade; unstable angina, symptomatic congestive heart failure, or prior myocardial infarction.\n4. Patients must not be receiving any additional medicines being given for the specific purpose of treating cancer. Alternative medications including, but not limited to cannabis-based products would not be a reason for exclusion.\n5. Patients with any medical or surgical conditions that would interfere with gastrointestinal absorption of oral agents.\n6. Patients may not have received prior cardiac irradiation.\n\nCohort 2 only:\n\n5\\. Patients must not have previously been enrolled in OstEvo","6 Years","49 Years",{"count":232,"type":21},45,[25],"The researchers are doing this study to find out whether adding gefitinib, trametinib, disulfiram, and sunitinib to standard chemotherapy is a more effective treatment approach for people with osteosarcoma than standard chemotherapy on its own. The researchers will also look at the safety of adding these drugs to standard chemotherapy. The researchers will also use the additional research biopsies from Cohort 1 participants to learn more about how osteosarcoma survives during chemotherapy.",[236,29],"Osteosarcoma",[238,239,240,241,242,243],"Gefitinib","Trametinib","Disulfiram","Sunitinib","Metastatic Osteosarcoma","25-257","2026-03-12",{"date":214,"type":34},{"date":247,"type":34},"2026-03-11",{"date":249,"type":21},"2028-03-11",{"name":251,"class":73},"Memorial Sloan Kettering Cancer Center",7,{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":261,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":263,"conditions":264,"keywords":271,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":275,"startDateStruct":277,"completionDateStruct":279,"leadSponsor":281,"locationsCount":74},"100623759","cervical-cancer-oligo-states-recurrence-metastasis-multicentre-outcomes-study-100623759","NCT07400809","Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.","Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.","Retro-COSMOS","Inclusion Criteria:\n\n1. Cervical cancer with (induced) oligo-metastatic and\u002For oligo-recurrent cervix cancer whether treated or not treated with radiation. These patients may have received previous treatment within or outside approved clinical trials\u002Fstudies.\n2. Patients with poly-metastatic disease with good response to systemic chemotherapy and treated with radiation to recurrence or metastatic site.\n3. Patients treated with radical doses at the time of first diagnosis of oligo-metastasis\u002Foligo-recurrence and present with further oligo-progression.\n4. Patients with oligo-metastasis or oligo-recurrence treated with other locally directed therapies (like surgery, ablation, etc.) are also permitted.\n\nExclusion Criteria:\n\n1. Gynaecological cancer other than cervical cancer.\n2. Persistent Poly-metastatic disease post systemic treatment\n3. Receiving investigational new drugs at the time of relapse as part of other ongoing trials.\n4. No clinical follow up after treatment",{"count":262,"type":21},350,"Systemic chemotherapy with or without palliative radiation represents the current standard of care in patients with recurrent or metastatic cervix cancer. In addition, pelvic radiotherapy including brachytherapy is also recommended. There is no consensus on the treatment of metastatic site in patients with oligo-metastatic or oligo-recurrent cervix cancer. Also, it is not clear if addition of local treatment to systemic chemotherapy benefits all patients with metastatic disease or a select few with limited systemic disease burden. It's presently unclear which patients derive maximum benefit with integration of radiation at both primary and metastatic site, who develop infield recurrence if performing salvage surgery, locally directed treatments or re-irradiation in addition to systemic chemotherapy improves overall outcomes. The heterogeneity in clinical practice provides an important opportunity to develop a framework for data collection and future studies within such subgroup of patients. In this retrospective study, we aim to determine overall survival, Infield progression free survival, overall progression free survival, dose response relationship of nodal and visceral progressions, and within setting of re-irradiation (infield progressions), severe adverse events and toxicity, risk groups identification, a nomogram which correlates risk groups with expected outcomes, and framework for tissue collection for translational research Investigators will record the parameters in a predesigned proforma without including personal identifiers.",[265,266,267,268,269,270,29],"Chemotherapy","Treatment Compliance","Radiotherapy","Cervix Cancer","Surgery","Recurrent",[272,273],"Recurrent and Metastatic Cervix Cancer","Oligo States","2026-02-12",{"date":276,"type":34},"2026-02-17",{"date":278,"type":34},"2023-08-23",{"date":280,"type":21},"2027-06-14",{"name":282,"class":283},"Tata Memorial Hospital","OTHER_GOV",{"id":285,"slug":286,"hasResults":12,"nctId":287,"briefTitle":288,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":292,"minAge":18,"maxAge":4,"enrollmentInfo":293,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":295,"conditions":296,"keywords":298,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":74},"100569885","clinical-and-dosimetric-study-of-patients-treated-with-177lu-psma-617-for-prostate-cancer-100569885","NCT06700057","Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.","Optimisation and Safety of an Innovative Nuclear Medicine Treatment: Clinical and Dosimetric Study of Patients Treated With 177Lu-PSMA-617 for Prostate Cancer.","DOSIPROSTATE","Inclusion Criteria:\n\n1. Patient aged 18 and over.\n2. Patient with indication for or having started or completed treatment with 177Lu-PSMA-617 since 01\u002F11\u002F2023:\n\n   1. Progressive, metastatic, castration-resistant prostate cancer,\n   2. overexpressing prostate specific membrane antigen (PSMA)\n   3. treated with taxane chemotherapy and at least one 2nd generation hormone therapy (apalutamide, enzalutamide, darolutamide, abiraterone-prednisone).\n3. Patient able to lie still for 1 hour for image acquisition.\n4. Patient's place of residence \\\u003C 2 hours' drive from the Institut Bergonié.\n5. Patient has not expressed any opposition to the use of his\u002Fher medical data for research purposes.\n\nExclusion Criteria:\n\nNone","MALE",{"count":294,"type":21},50,"Single-centre, retrospective and prospective observational study. This study aims to evaluate the dose delivered by radiation to the tumour and organs at risk, as a factor predicting response and the appearance of toxicities. Dosimetric calculations are made for each treatment using scintigraphic images acquired following injection of 177Lu-PSMA-617.",[297,29],"Prostate Cancer",[299],"Radiopharmaceutical drug","2026-01-28",{"date":302,"type":34},"2026-01-30",{"date":304,"type":34},"2023-11-01",{"date":306,"type":21},"2027-12-31",{"name":308,"class":73},"Institut Bergonié",{"id":310,"slug":311,"hasResults":12,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":4,"eligibilityCriteria":315,"healthyVolunteers":12,"sex":316,"minAge":18,"maxAge":4,"enrollmentInfo":317,"targetDuration":4,"studyType":22,"phases":319,"briefSummary":320,"conditions":321,"keywords":329,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":74},"100480932","phase-1-onc201-and-atezolizumab-in-obesity-driven-endometrial-cancer-100480932","NCT05542407","ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer","Phase 1 Clinical Trial of ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer","In order to participate in this study a subject must meet all of the eligibility criteria outlined below.\n\nInclusion Criteria\n\n1. Ability to understand and willingness to sign a written informed consent obtained to participate in the study and HIPAA authorization for release of personal health information.\n2. Age ≥ 18 years at the time of consent.\n3. ECOG Performance Status of 0, 1, or 2\n4. Histologically confirmed metastatic or recurrent EC (endometrioid, carcinosarcoma, serous, clear cell, adeno-squamous and mixed histologies).\n5. Subjects must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria\n6. Must have radiographic disease progression after at least 1 line of systemic cytotoxic therapy for metastatic disease or with progression within 12 months of completing adjuvant chemotherapy.\n7. Life expectancy of at least 3 months.\n8. Demonstrate adequate organ function as defined in the table below; all screening labs to be obtained within 72 hours prior to initiating study treatment.\n\nExclusion Criteria\n\n1. Prior treatment with ONC201.\n2. Prior treatment with CD137 agonists or immune checkpoint blockade therapies, including antiCTLA-4, and anti PD-L1 therapeutic antibodies\n3. Treatment with another investigational agent or participation in another clinical trial within the last 28 days prior to initiating protocol therapy.\n4. Subjects who have had chemotherapy or radiotherapy within 4 weeks prior to study treatment or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to initiating protocol therapy.\n5. Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of protocol therapy Subjects receiving prophylactic antibiotics (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible for the study.\n6. Treatment with systemic immunostimulatory agents (including, but not limited to, interferon and interleukin 2 \\[IL-2\\]) within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of protocol therapy.\n7. Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti TNF-agents) within 2 weeks prior to initiation","FEMALE",{"count":318,"type":21},58,[24],"Endometrial cancer (EC) is the fourth most common cancer in United States women, and alarmingly, the frequency and mortality from EC continues to rise, in part due to the obesity epidemic. Obese women with EC have a 6.3-fold increased risk of death from this disease, as compared to their non-obese counterparts. Patients with advanced\u002Frecurrent EC are unlikely to be cured by surgery, conventional chemotherapy (paclitaxel + carboplatin is the standard first-line treatment), radiation, or a combination of these. Thus, new treatments for EC are desperately needed as well as a better understanding of the impact of obesity on EC biology and treatment.\n\nThe purpose of this study is to test the safety of a combination of treatments, atezolizumab and ONC201, given based on body weight, to treat endometrial cancer. Using the combination of atezolizumab and ONC201, has not been approved by the Food and Drug Administration (FDA) for the treatment of endometrial cancer. This clinical trial will examine the treatment of atezolizumab + ONC201 in obese and non-obese subjects with metastatic\u002Frecurrent EC.",[322,29,323,324,325,326,327,328],"Endometrial Cancer","Endometrioid Endometrial Cancer","Carcinosarcoma","Serous Adenocarcinoma of Endometrium (Diagnosis)","Clear Cell Endometrial Carcinoma","Endometrial Endometrioid Adenocarcinoma","Endometrial Mixed Cell Adenocarcinoma",[330,331,332],"Atezolizumab","ONC201","obesity","2026-01-27",{"date":335,"type":34},"2026-01-29",{"date":337,"type":34},"2023-10-23",{"date":339,"type":21},"2028-07-31",{"name":341,"class":73},"UNC Lineberger Comprehensive Cancer Center",{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":22,"phases":351,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":357,"lastUpdatePostDateStruct":358,"startDateStruct":360,"completionDateStruct":362,"leadSponsor":364,"locationsCount":74},"100465280","phase-1-study-of-pat-in-patients-with-solid-tumor-cancers-100465280","NCT05338658","Study of PAT in Patients With Solid Tumor Cancers","Phase I Study of Peptide Alarm Therapy (PAT) Administered by Intratumoral Injection With a PD-1\u002FPD-L1 Inhibitor in Patients With Solid Tumor Cancers Who Have Failed 1 or More Prior Therapies","Inclusion Criteria:\n\n* Must be seropositive for CMV and EBV.\n* Must have at least one HLA-A\\*0201 allele. This screening can be performed after determining CMV and EBV seropositivity is established or, if available, from the results of previous tumor profiling by any CLIA-certified lab (i.e. Caris, FoundationOne).\n* 18 years or older at the time of signing the pre-screening consent.\n* ECOG Performance Status 0 or 1.\n* Adequate organ function within 14 days of study enrollment\n* Cardiac: New York Heart Association (NYHA) Functional Classification Class I.\n* Pulmonary: oxygen saturation ≥ 90% on room air.\n* Time between last dose of prior anti-cancer therapy and Day 1 of this study:\n\n  * Chemotherapy: a minimum of 28 days since last treatment.\n  * Targeted therapy, immunotherapy, investigational agents: a minimum of 45 days since last dose (at least 2 months for anti-VEGF)\n  * Prior palliative radiotherapy within 7 days of start of study treatment. Participants must have recovered from all radiation-related toxicities (prior irradiation to targeted lesions is not permitted)\n* Must have recovered to CTCAE ≤Grade 1 from previous treatment related acute toxicities.\n* Persons of childbearing potential or with partners of childbearing potential must be willing to abstain from heterosexual activity or to use a highly effect form of contraception from the time of study enrollment until at least 4 months after the last dose of PD-1\u002FPD-L1 inhibitor.\n* Able to understand and provide voluntary written consent prior to the performance of any research related activity.\n\nExclusion Criteria:\n\n* Pregnant or breast feeding.\n* Requires therapeutic anticoagulation for which it is deemed unsafe to discontinue anticoagulation for 5 days prior to Cycle 1 through Day 7 of Cycle 1\n* Class II or greater New York Heart Association Functional Classification criteria or serious cardiac arrhythmias likely to increase the risk of cardiac complications of therapy (e.g. ventricular tachycardia, frequent ventricular ectopy, or supraventricular tachyarrhythmia requiring chronic therapy)\n* Known active CNS metastases\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).\n* Has received a live vaccine within 30 days prior to the first dose of study drug.\n* Diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to study enrollment.\n* Prior bone marrow and\u002For solid organ transplant.\n* Has severe hypersensitivity (≥Grade 3) to prior PD-1\u002FPD-L1 and\u002For any of its excipients.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Has an active infection requiring systemic therapy.\n* Known seropositive for HIV or known active Hepatitis B or C infection with detectable viral load by PCR\n* Known history of active TB (Bacillus Tuberculosis)\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment.\n* Has uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, interstitial lung disease, non-infectious pneumonitis, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements in the opinion of the treating investigator.",{"count":350,"type":21},21,[24],"This is a single center Phase I study with extension of peptide alarm therapy (PAT) administered by intratumoral (IT) injection during the 1st course of a standard of care intravenous PD-1\u002FPD-L1 inhibitor for the treatment of locally advanced or metastatic solid tumor cancers that has failed to be controlled after one or more prior therapies including a previous PD-1\u002FPD-L1 inhibitor",[29,354],"Solid Tumor",[356],"PAT","2025-12-08",{"date":359,"type":34},"2025-12-09",{"date":361,"type":34},"2023-05-19",{"date":363,"type":21},"2027-01",{"name":365,"class":73},"Masonic Cancer Center, University of Minnesota",{"id":367,"slug":368,"hasResults":12,"nctId":369,"briefTitle":370,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":12,"sex":316,"minAge":18,"maxAge":82,"enrollmentInfo":373,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":375,"conditions":376,"keywords":380,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":74},"100604826","rapid-assessment-of-sentinel-lymph-node-metastasis-status-using-a-pan-ck-targeting-nir-ii-fluorescent-probe-in-breast-cancer-100604826","NCT07154563","Rapid Assessment of Sentinel Lymph Node Metastasis Status Using a Pan-CK-targeting NIR-II Fluorescent Probe in Breast Cancer","NIR-II","Inclusion Criteria:\n\n* Adult patients between 18-75 years of age\n* Patients presenting with a breast nodule or mass presumed to be resectable on pre-operative assessment\n* Breast cancer patients who are scheduled to undergo sentinel lymph node biopsy or axillary lymph node dissection;\n* Good operative candidate\n* Subject capable of giving informed consent and participating in the process of consent\n\nExclusion Criteria:\n\n* Patients unable to participate in the consent process\n* Patients had contraindications to surgery, such as serious cardiopulmonary disease, coagulation dysfunction, etc",{"count":374,"type":21},60,"Breast malignant tumors are a serious threat to women's health, and the current treatment for breast malignant tumors is still dominated by surgery, but the problems faced by patients after surgery such as edema and tumor recurrence are still relatively common, and the high recurrence rate and the occurrence of postoperative complications are closely related to the removal of metastatic lymph nodes during surgery. Therefore, accurate assessment of sentinel lymph node (SLN) metastases is essential to determine the extent of axillary lymph node dissection (ALND) and minimize complications. In this study, we developed a new technique that can rapidly distinguish between metastatic lymph nodes and normal sentinel lymph nodes (SLNs) in breast cancer patients. Briefly, fresh tissue is incubated with the probe and imaged immediately after intraoperative sentinel lymph node resection to identify the metastatic status of SLN. The accuracy of fluorescence imaging is confirmed by pathological diagnosis.",[377,378,379,29],"Breast Cancer Metastatic","Sentinel Lymph Node","Sentinel Lymph Node Biopsy (SLNB)",[371,185,378,29],"2025-08-27",{"date":383,"type":34},"2025-09-04",{"date":385,"type":34},"2025-02-01",{"date":387,"type":21},"2026-12-01",{"name":389,"class":73},"Yunnan Cancer Hospital",{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":394,"acronym":4,"eligibilityCriteria":395,"healthyVolunteers":178,"sex":17,"minAge":18,"maxAge":396,"enrollmentInfo":397,"targetDuration":399,"studyType":209,"phases":4,"briefSummary":400,"conditions":401,"keywords":405,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":417},"100569186","prostate-specific-membrane-antigen-petct-imaging-in-psma-related-disease-patients-100569186","NCT06690970","Prostate Specific Membrane Antigen PET\u002FCT Imaging in PSMA-Related Disease Patients","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled PSMA PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.","80 Years",{"count":398,"type":21},500,"7 Days","To evaluate the potential usefulness of 68Ga\u002F18F-PSMA\u002FPSFA positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various PSMA-related disease patients.",[402,297,403,29,404],"PSMA-related Disease","Positron Emission Tomography","FAP",[406,407,404],"PET\u002FCT","PSMA","2025-08-07",{"date":410,"type":34},"2025-08-11",{"date":412,"type":34},"2020-09-01",{"date":414,"type":21},"2027-12-01",{"name":416,"class":73},"Tianjin Medical University",2,{"id":419,"slug":420,"hasResults":12,"nctId":421,"briefTitle":422,"officialTitle":423,"acronym":4,"eligibilityCriteria":424,"healthyVolunteers":12,"sex":316,"minAge":18,"maxAge":82,"enrollmentInfo":425,"targetDuration":4,"studyType":22,"phases":427,"briefSummary":428,"conditions":429,"keywords":432,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":436,"lastUpdatePostDateStruct":437,"startDateStruct":439,"completionDateStruct":441,"leadSponsor":443,"locationsCount":417},"100596069","comparison-of-two-position-and-four-position-cervical-injection-techniques-for-sentinel-lymph-node-mapping-in-endometrial-cancer-using-methylene-blue-100596069","NCT07040657","Comparison of Two-Position and Four-Position Cervical Injection Techniques for Sentinel Lymph Node Mapping in Endometrial Cancer Using Methylene Blue","Comparison of Two-Point and Four-Point Cervical Injection Techniques Using Methylene Blue for Sentinel Lymph Node Mapping in Endometrial Cancer","Inclusion Criteria:\n\n* Individuals diagnosed with stage I endometrial cancer based on CT and PET-CT imaging.\n* Individuals with a pathologically confirmed diagnosis of stage I endometrial cancer.\n\nExclusion Criteria:\n\nMedical Conditions\n\n* Individuals diagnosed with dementia.\n* Individuals with allergies to methylene blue or iodine.\n* Individuals who have received active treatment for another malignancy within the past five years.\n* Inability to successfully perform PLD (pelvic lymphadenectomy) or history of prior PLD.\n* Women with multiple and confluent lymph nodes identified as positive on FDG-PET\u002FCT (such cases are not considered stage I).\n\nCancer-Related Conditions\n\n* Individuals with clinically or radiologically identified positive lymph nodes or metastatic disease.\n* Individuals with a history of pelvic dissection and\u002For radiation therapy.\n* Individuals with advanced cervical or uterine cancer.\n* Individuals with T3\u002FT4 lesions.\n* Individuals with cervical tumors larger than 2 cm.\n\nOrgan Dysfunction\n\n• Individuals with hepatic dysfunction and a MELD score ≥ 10 and creatinine ≥ 2·0 mg\u002Fdl patients.",{"count":426,"type":21},100,[111],"This clinical trial evaluates lymph node mapping in newly diagnosed endometrial cancer patients undergoing surgery. The standard technique uses a 2-point methylene blue cervical injection. The study aims to determine if increasing injection points improves mapping success.",[430,431,378,29],"Endometrial Neoplasms","Endometrial Cancer Stage I",[433,434,60,435],"endometrial neoplasm","methylene blue","cervix","2025-06-18",{"date":438,"type":34},"2025-06-27",{"date":440,"type":34},"2025-05-01",{"date":442,"type":21},"2026-11-01",{"name":444,"class":73},"Dokuz Eylul University",{"id":446,"slug":447,"hasResults":12,"nctId":448,"briefTitle":449,"officialTitle":450,"acronym":4,"eligibilityCriteria":451,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":452,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":464,"locationsCount":74},"100592444","real-world-study-of-skb264-monotherapy-or-combination-therapy-in-recurrent-or-metastatic-her2-negative-breast-cancer-100592444","NCT06993506","Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer","Sacituzumab Tirumotecan Monotherapy or Combination Therapy in Patients With Unresectable Locally Advanced, Recurrent or Metastatic HER2-Negative Breast Cancer: A Real-World Study","Inclusion Criteria:\n\n1. Aged ≥ 18 years old at the time of signing the informed consent form, regardless of gender;\n2. Patient must meet one of the following pathological diagnoses and classifications:\n\n   2.1) For TNBC Cohort: -Histological\u002Fcytological confirmed of triple-negative breast cancer (TNBC) from the most recent pre-SKB264 biopsy\u002Fpathological report, with: HER2 negative: immunohistochemistry (IHC) of 0 or 1+; if is 2+ by IHC, negative HER2 expression must be confirmed by fluorescence in situ hybridization (FISH); Estrogen and progesterone receptor negative means that less than 1% of the cells express hormone receptors as indicated by IHC; -Locally advanced, recurrent, or metastatic disease (locally advanced disease should be confirmed by investigators as ineligible for curative resection); 2.2) For HR+\u002FHER2- BC Cohort: -Histological\u002Fcytological confirmed of HR+\u002FHER2- breast cancer from the most recent pre-SKB264 biopsy\u002Fpathological report, with: HER2 negative: IHC of 0 or 1+; if is 2+ by IHC, negative HER2 expression must be confirmed by FISH; HR positive: Hormone receptor-positive (HR, ER, or PR status) was defined as ≥1% expression by IHC.-Locally advanced, recurrent, or metastatic disease (locally advanced disease should be confirmed by investigators as ineligible for curative resection);\n3. Plan to receive SKB264 monotherapy or combination therapy;\n4. Prior treatment lines: -For TNBC Cohort: ≤2 lines of systemic antitumor therapy for unresectable locally advanced, recurrent, or metastatic disease; -For HR+\u002FHER2- BC Cohort: ≤2 lines of systemic antitumor therapy (excluding endocrine therapy) for unresectable locally advanced, recurrent, or metastatic disease;\n5. Voluntarily participate in the study, sign the informed consent form and demonstrate good compliance.\n\nExclusion Criteria:\n\n1. Patients with other malignancies, except cured basal or squamous cell skin cancer or in situ cancer of cervix; and patients with other malignancies must have a tumor-free period of at least 5 years;\n2. Patients who are currently participating in other interventional clinical studies;\n3. Known allergy to the investigational drug or any of its components;\n4. Pregnant or lactating women;\n5. Any situation that the researchers consider to interfere with the evaluation of the study drug or the safety of the subjects or the analysis of the study results, or any other situation that the researchers consider inappropriate to participate in this study.",{"count":398,"type":21},"This study is a multi-center observational real-world study, with a total of 500 patients planned to be enrolled. This study is divided into two cohorts: the triple-negative breast cancer (TNBC) cohort and the hormone receptor-positive\u002Fhuman epidermal growth factor receptor 2-negative breast cancer (HR+\u002F HER2-BC) cohort. The aim of this study is to assess the efficacy and safety of Sacituzumab Tirumotecan (SKB264) monotherapy or combination therapy in patients with unresectable locally advanced, recurrent or metastatic HER2-negative breast cancer in the real-world setting.",[455,456,29],"HER2-negative Breast Cancer","Recurrence","2025-05-20",{"date":459,"type":34},"2025-05-29",{"date":461,"type":21},"2025-08-01",{"date":463,"type":21},"2027-10-31",{"name":465,"class":73},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":4,"eligibilityCriteria":472,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":22,"phases":475,"briefSummary":476,"conditions":477,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":485,"lastUpdatePostDateStruct":486,"startDateStruct":488,"completionDateStruct":490,"leadSponsor":492,"locationsCount":74},"100528795","phase-2-definitive-radiation-for-high-risk-spine-metastases-100528795","NCT06165419","Definitive Radiation for High-Risk Spine Metastases","A Phase II Study Evaluating Definitive Radiosurgical Decompression in Patients With High-Risk Spinal Metastases","Eligible patients must have:\n\n* Any pathologically proven solid tumor diagnosis not of central nervous system origin with radiographic or pathologic evidence of metastatic disease\n* Metastatic spine involvement documented by imaging\n* Involvement of maximum 3 contiguous vertebral bodies at the index site\n* Intact neurologic function, or only minor neurologic deficits with muscle strength greater or equal to 4 out of 5 with or without steroids\n* An evaluation by an radiation oncology and orthopedic spine\u002Fneurosurgery attending\n* ECOG Performance Status of 0-3\n\nPatients are ineligible if they have:\n\n* An unstable spine defined as a Spinal Instability Neoplastic Score (SINS) greater than 12\n* Had previous surgery or radiation to address the target spinal metastases\n* Radiosensitive tumors (e.g. small cell lung cancer, lymphoma, multiple myeloma, and germ-cell tumors)",{"count":474,"type":21},26,[25],"This study is looking at whether patients with cancer that has aggressively spread to the spine can be treated with stereotactic body radiation therapy only and avoid a large spine surgery",[478,479,480,481,482,483,484,29],"Metastatic Cancer","Metastatic Lung Cancer","Metastatic Breast Cancer","Metastatic Tumor","Metastatic Tumor of Bone","Metastatic Tumor to the Spine","Spine Metastases","2025-05-09",{"date":487,"type":34},"2025-05-14",{"date":489,"type":34},"2023-12-14",{"date":491,"type":21},"2026-05-31",{"name":493,"class":73},"Stony Brook University",{"id":495,"slug":496,"hasResults":12,"nctId":497,"briefTitle":498,"officialTitle":499,"acronym":500,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":503,"conditions":504,"keywords":507,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":512,"lastUpdatePostDateStruct":513,"startDateStruct":515,"completionDateStruct":517,"leadSponsor":519,"locationsCount":74},"100588790","validation-of-a-mirna-panel-to-optimize-treatment-response-in-patients-with-metastatic-pancreatic-cancer-mirpanc-2-100588790","NCT06945978","Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirPANC 2)","Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer","mirPANC 2","Inclusion Criteria:\n\n* Patients diagnosed with metastatic PDAC;\n* Patients who will start treatment with FOLFIRINOX;\n* 18 years or older;\n* Who agree to participate in the study by signing the Informed Consent Form;\n\nExclusion Criteria:\n\n* Patients who have previously undergone chemotherapy, whether neoadjuvant, adjuvant, or any prior first-line treatment;\n* Patients who do not meet the minimum criteria to receive the proposed regimen, such as those with hyperbilirubinemia, those who are not candidates due to age or performance status deterioration;",{"count":374,"type":21},"This study is being conducted to better understand how pancreatic cancer behaves during treatment and how we can improve methods for monitoring disease progression. The research aims to determine whether small molecules present in the blood, called miRNAs, can help doctors assess whether the treatment is working or needs adjustment. With this, we hope to make cancer monitoring less invasive and more precise, allowing patients to receive more personalized and effective treatments.",[505,29,506],"Pancreatic Cancer","Epigenetic",[508,509,510,506,511],"Pancreatic cancer","miRNA","Treatment response","Folfirinox","2025-04-22",{"date":514,"type":34},"2025-04-27",{"date":516,"type":34},"2025-01-21",{"date":518,"type":21},"2027-12",{"name":520,"class":73},"Benedito Mauro Rossi",{"id":522,"slug":523,"hasResults":12,"nctId":524,"briefTitle":525,"officialTitle":525,"acronym":4,"eligibilityCriteria":526,"healthyVolunteers":12,"sex":316,"minAge":18,"maxAge":82,"enrollmentInfo":527,"targetDuration":4,"studyType":22,"phases":529,"briefSummary":530,"conditions":531,"keywords":534,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":536,"lastUpdatePostDateStruct":537,"startDateStruct":539,"completionDateStruct":541,"leadSponsor":542,"locationsCount":74},"100559685","a-multi-mode-thermophysical-immunotherapy-study-for-breast-cancer-liver-metastases-100559685","NCT06567353","A Multi-mode Thermophysical Immunotherapy Study for Breast Cancer Liver Metastases","Inclusion Criteria:\n\n1. Age 18-75 years, female gender;\n2. Pathologically confirmed breast cancer liver metastases, in patients who are unable to tolerate or refuse surgical resection;\n3. The number of lesions ≤ 3, with any single lesion diameter ≤ 4cm;\n4. At least an interval of 1 month since the last local treatment;\n5. Child-Pugh class A or B;\n6. ECOG PS score ≤2, with an expected survival of \\>3 months.\n\nExclusion Criteria:\n\n1. Liver function Child-Pugh class C;\n2. Systemic widespread metastasis, with an expected survival of \\\u003C 3 months;\n3. History of esophageal (gastric fundus) variceal bleeding within the past month;\n4. Dysfunction or failure of vital organs;\n5. Presence of an active infection;\n6. Irreparable coagulation abnormality;\n7. Refractory massive ascites, pleural effusion or cachexia;\n8. Pregnancy, altered consciousness or patients unable to cooperate with treatment;\n9. Previously participated in other clinical studies and still within the follow-up period;\n10. Any other factors deemed inappropriate for inclusion or that may affect the patient's participation in the study, as determined by the investigator.",{"count":528,"type":21},10,[111],"This is a single-center, parallel-controlled clinical study designed to evaluate the safety, efficacy and impact on systemic anti-tumor immunity of a multi-mode integrated ablation system for the treatment of breast cancer liver metastases.",[532,533,29],"Breast Neoplasms","Liver Neoplasms",[535],"Multi-mode Thermophysical Immunotherapy","2025-03-12",{"date":538,"type":34},"2025-03-14",{"date":540,"type":34},"2024-12-09",{"date":518,"type":21},{"name":543,"class":73},"Ruijin Hospital",{"id":545,"slug":546,"hasResults":12,"nctId":547,"briefTitle":548,"officialTitle":548,"acronym":4,"eligibilityCriteria":549,"healthyVolunteers":178,"sex":17,"minAge":18,"maxAge":396,"enrollmentInfo":550,"targetDuration":399,"studyType":209,"phases":4,"briefSummary":551,"conditions":552,"keywords":555,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":560,"startDateStruct":562,"completionDateStruct":564,"leadSponsor":566,"locationsCount":74},"100569185","somatostatin-receptor-petct-in-sstr-related-disease-patients-100569185","NCT06690957","Somatostatin Receptor PET\u002FCT in SSTR-Related Disease Patients","Inclusion Criteria:\n\n\\- (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled SSTR PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n\\- (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":398,"type":21},"To evaluate the potential usefulness of 68Ga\u002F18F-TATE\u002FJR11\u002FLM3 positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various SSTR-related disease patients.",[553,554,403,29],"SSTR-related Disease","Tumor",[406,556,557,558],"SSTR","Angonist","Antagonist","2025-02-07",{"date":561,"type":34},"2025-02-11",{"date":563,"type":34},"2019-02-01",{"date":565,"type":21},"2027-10-01",{"name":416,"class":73},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":571,"acronym":4,"eligibilityCriteria":572,"healthyVolunteers":178,"sex":17,"minAge":18,"maxAge":396,"enrollmentInfo":573,"targetDuration":4,"studyType":22,"phases":575,"briefSummary":576,"conditions":577,"keywords":579,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":583,"startDateStruct":584,"completionDateStruct":586,"leadSponsor":587,"locationsCount":74},"100569168","chemokine-receptor-4-petct-imaging-of-cxcr4-related-diseases-100569168","NCT06690736","Chemokine Receptor 4 PET\u002FCT Imaging of CXCR4-Related Diseases","Inclusion Criteria:\n\n* suspected or confirmed untreated Lymphoproliferative and other CXCR4-related diseases patients\n* 18F-FDG PET\u002FCT within two weeks\n* signed written consent.\n\nExclusion Criteria:\n\n* pregnancy\n* breastfeeding\n* known allergy against Pentixafor",{"count":574,"type":21},200,[111],"To evaluate the potential usefulness of 68Ga\u002F18F-Pentixafor\u002FPentixather positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various CXCR4-related disease patients.",[578,554,403,29],"CXCR4-related Disease",[406,580,581,582],"Chemokine receptor 4","Pentixafor","Pentixather",{"date":561,"type":34},{"date":585,"type":34},"2022-03-01",{"date":565,"type":21},{"name":416,"class":73},{"id":589,"slug":590,"hasResults":12,"nctId":591,"briefTitle":592,"officialTitle":592,"acronym":4,"eligibilityCriteria":593,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":396,"enrollmentInfo":594,"targetDuration":399,"studyType":209,"phases":4,"briefSummary":595,"conditions":596,"keywords":598,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":559,"lastUpdatePostDateStruct":600,"startDateStruct":601,"completionDateStruct":602,"leadSponsor":603,"locationsCount":74},"100568963","fapi-petct-in-various-fap-related-disease-patients-100568963","NCT06688071","FAPI PET\u002FCT in Various FAP-Related Disease Patients","Inclusion Criteria:\n\n* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled FAPI PET\u002FCT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.\n\nExclusion Criteria:\n\n* (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.",{"count":398,"type":21},"To evaluate the potential usefulness of 68Ga\u002F18F-FAPI positron emission tomography\u002Fcomputed tomography (PET\u002FCT) for the diagnosis of primary and metastatic lesions in various FAP-related disease patients.",[597,554,403,29],"FAP-related Disease",[406,404,599],"FAPI",{"date":561,"type":34},{"date":585,"type":34},{"date":565,"type":21},{"name":416,"class":73},{"id":605,"slug":606,"hasResults":12,"nctId":607,"briefTitle":608,"officialTitle":609,"acronym":4,"eligibilityCriteria":610,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":611,"targetDuration":4,"studyType":22,"phases":612,"briefSummary":614,"conditions":615,"keywords":618,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":619,"lastUpdatePostDateStruct":620,"startDateStruct":622,"completionDateStruct":624,"leadSponsor":626,"locationsCount":4},"100571378","phase-2-a-clinical-trial-to-evaluate-effect-of-iae0972-combined-with-chemotherapy-for-rm-hnscc-or-npcnote-it-is-currently-phase-ii-100571378","NCT06719479","A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R\u002FM HNSCC or NPC(Note: It is Currently Phase II.).","A Phase II\u002FIII Clinical Trial to Evaluate the Effect of IAE0972 Combined with Chemotherapy Selected by Doctors for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma\u002FNasopharyngeal Carcinoma.","Inclusion Criteria:\n\n1. The age is 18\\~75 years old (including the critical value), regardless of gender.\n2. Phase II cohort 1, cohort 2: locally advanced squamous cell carcinoma of the head and neck which only occurred in the oral cavity, oropharynx, hypopharynx and larynx after histological diagnosis or had no indication of radical local treatment; In the past, I only received ≤2 line therapy for recurrent and metastatic head and neck squamous cell carcinoma.\n3. Phase II cohort 3, cohort 4, cohort 5: Histologically confirmed nasopharyngeal carcinoma, stage IVb or recurrent nasopharyngeal carcinoma that is not suitable for local treatment according to the TNM of AJCC nasopharyngeal carcinoma in the 8th edition of 2017; In the past, they only received ≤2 line therapy for recurrent and metastatic nasopharyngeal carcinoma.\n4. According to the researcher's judgment, the chemotherapy in this experiment is applicable.\n5. According to the RECIST 1.1 standard, there is at least one measurable lesion (tumor lesions located in previous radiotherapy areas or other local regional treatment sites are generally not regarded as measurable lesions, unless the lesions make clear progress or persist after radiotherapy for three months).\n6. The score of physical condition of the ECOG is 0\\~1.\n7. The estimated survival time is ≥3 months.\n8. Have sufficient organ functions:\n\n   * Blood system (no blood transfusion or hematopoietic stimulating factor treatment within 14 days): ANC≥1.5×109\u002FL, PLT≥90×109\u002FL, HGB≥ 90 g\u002FL; ② Liver function: TBIL≤1.5 times the ULN, except Gilbert syndrome; AST and ALT are ≤3.0 times ULN, while subjects with liver metastasis or liver cancer need AST and ALT≤3.0 times ULN and total bilirubin ≤ 3.0 times ULN;\n\n     * Renal function: Cr≤1.5 times ULN; If the creatinine is more than 1.5 times ULN, the CCR should be ≥ 50 ml\u002Fmin (calculated according to Cockcroft-Gault formula);\n\n       * Coagulation function: INR≤1.5 times ULN, APTT≤1.5 times ULN, and INR and APTT≤2.5 times ULN for patients with liver metastasis or liver cancer.\n9. Qualified fertile subjects (male and female) must agree to use reliable contraceptive methods (hormone or barrier method or abstinence) with their partners during the trial and at least 6 months after the last medication; The blood pregnancy test of female subjects of childbearing age must be negative within 7 days before the first use of the study drug.\n10. Subjects must give informed consent to this study before the experiment, and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Having received chemotherapy, radiotherapy, biotherapy, endocrine therapy, immunotherapy and other anti-tumor treatments within 4 weeks before the first use of the investigating drug, the following drugs should be excluded according to the following criteria:\n\n   ① Nitrosourea or mitomycin C was used within 6 weeks before the first use of the study drug;\n\n   ② Oral administration of fluorouracil and small molecule targeted drugs 2 weeks before the first use of the study drug or within 5 half-lives of the drug (whichever is longer);\n\n   ③ Chinese patent drugs with anti-tumor indications were used within 2 weeks before the first use of the study drugs.\n2. Received other unlisted clinical research drugs or treatments within 4 weeks before using the research drugs.\n3. The adverse reactions of previous anti-tumor treatments have not recovered to NCI CTCAE 5.0 grade evaluation ≤1 grade or the relevant provisions of the selection criteria (except for the toxicity that the researchers judged to have no safety risk, such as alopecia, grade 2 peripheral neurotoxicity, hypothyroidism stabilized by hormone replacement therapy, etc.).\n4. It is known that it has hypersensitivity to any antibody drugs (NCI CTCAE 5.0 rating is ≥3), or it has hypersensitivity to research drugs, active ingredients or inactive excipients of chemotherapy schemes.\n5. Have received major surgery (excluding puncture biopsy), major trauma or need to undergo elective surgery during the trial within 4 weeks before the first use of the study drug.\n6. Having received systemic corticosteroids (prednisone \\> 10 mg\u002Fday or similar drugs with the same dose) within 14 days before the first use of the study drug, except for the following cases: using topical, ophthalmic, intra-articular and intranasal corticosteroids; Short-term use of glucocorticoids for preventive treatment (for example, prevention of contrast agent allergy).\n7. Treatment with other immunosuppressants within 28 days or 5 half-lives (whichever is longer) before the first use of the study drug.\n8. Have used immunomodulatory drugs within 14 days before the first use of the study drug (Appendix 5).\n9. Have been vaccinated with any live vaccine within 4 weeks before the first use of the study drug.\n10. Received allogeneic hematopoietic stem cell transplantation or organ transplantation in the past.\n11. Brain parenchymal metastasis or meningeal metastasis with clinical symptoms.\n12. It has active infection and needs intravenous anti-infection treatment at present.\n13. Have a history of immunodeficiency disease, including positive detection of HIV antibody.\n14. Active hepatitis B (HBsAg positive and HBV-DNA positive or above the upper limit of normal value) and active hepatitis C (HCV antibody positive and HCV RNA positive or above the upper limit of normal value).\n15. Having serious and uncontrollable lung diseases (severe infectious pneumonia, interstitial lung disease, etc.).\n16. Have a serious history of cardiovascular and cerebrovascular diseases, including but not limited to:\n\n    ① Severe cardiac rhythm or conduction abnormality, such as ventricular arrhythmia requiring clinical intervention and II-III degree atrioventricular block;\n\n    ② The mean QT interval (QTcF) corrected by Fridericia method was≥470 ms；\n\n    ③ Acute coronary syndrome, congestive heart failure, aortic dissection, stroke or other cardiovascular and cerebrovascular events of grade 3 or above occurred within 6 months before the first administration; (4) There is heart failure or LVEF less than 50% with the NYHA cardiac function classification ≥II or structural heart disease with high risk judged by other researchers;\n\n    ⑤ Clinically uncontrollable hypertension.\n17. Suffering from active autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, vasculitis, etc.), with the exception of clinically stable autoimmune thyroiditis, type I diabetes, vitiligo, cured atopic dermatitis in children, psoriasis that does not require systemic treatment (within the past 2 years), etc.\n18. Suffering from other malignant tumors within 5 years before the start of study administration, except for the following cases: malignant tumors that can be expected to be cured after treatment (including but not limited to thyroid cancer, cervical carcinoma in situ, basal or squamous cell skin cancer or breast ductal carcinoma in situ treated by radical surgery).\n19. There is clinically uncontrollable effusion in the third space, which is judged by the researcher to be unsuitable for the group.\n20. Known alcohol or drug dependence.\n21. Have mental disorder or poor compliance.\n22. Pregnant or lactating women.\n23. The researcher thinks that the subject has other serious history of systemic diseases, or is not suitable to participate in this clinical study for other reasons.",{"count":374,"type":21},[25,613],"PHASE3","Phase II: To evaluate the safety and tolerability of IAE0972 combined with chemotherapy selected by doctors for R\u002FM HNSCC\u002FNPC after failure or progress of ≤2-line system therapy, and to determine the MTD of combined therapy.\n\nPhase III: According to the RECIST 1.1, the effectiveness of IAE0972 combined with chemotherapy regimen chosen by doctors compared with placebo plus chemotherapy regimen chosen by doctors was evaluated through OS in patients with R\u002FM NPC who failed or progressed after treatment with ≤2-line system.",[616,617,456,29],"NPC","HNSCC",[616,617,456,29],"2024-12-02",{"date":621,"type":34},"2024-12-05",{"date":623,"type":21},"2025-01-01",{"date":625,"type":21},"2028-01-01",{"name":627,"class":41},"SUNHO（China）BioPharmaceutical CO., Ltd.",{"id":629,"slug":630,"hasResults":12,"nctId":631,"briefTitle":632,"officialTitle":633,"acronym":4,"eligibilityCriteria":634,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":635,"targetDuration":637,"studyType":209,"phases":4,"briefSummary":638,"conditions":639,"keywords":642,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":648,"lastUpdatePostDateStruct":649,"startDateStruct":651,"completionDateStruct":653,"leadSponsor":655,"locationsCount":350},"100511010","the-impact-of-radiotherapy-on-oligometastatic-cancer-100511010","NCT05933876","The Impact of Radiotherapy on Oligometastatic Cancer","Stereotactic ABlative Radiotherapy (SABR) in Oligometastatic Cancer (OC): a Radiomics, Multi-omics, and Machine Learning Approach to Clinical Decision-making. the OC-SABR Multicentric Project","Inclusion Criteria:\n\n* Histologic confirmation of primary tumor: breast, prostate, lung, colorectal.\n* 18 years old or older.\n* Up to five metastases located in the bone, lung, node, liver or brain.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status Scale 0 or 1.\n\nExclusion Criteria:\n\n* Non-melanoma skin cancer.\n* Previous radiotherapy in the same anatomic location.\n* Presence of vascular collagen disease.\n* Pregnancy or lactation at the time of inclusion.",{"count":636,"type":21},2000,"5 Years","Metastases represent the most threatening challenge in cancer. One of the management strategies for patients with Oligometastatic Cancer (OC) is Stereotactic ABlative Radiotherapy (SABR). However, there are few studies, and there is no defined clinical standard, nor are the radiobiological mechanisms that contribute to treatment response well understood. The focus should be on generating evidence to guide the personalization of radiotherapy beyond solely technological and anatomical precision. This could be achieved by recollecting clinical and biological data from patients that undergo this treatment and analyzing them to ultimately predict, with the help of artificial intelligence, which patients will be the most beneficiary and improve their survival rate.",[29,480,640,641,479],"Metastatic Prostate Cancer","Metastatic Colorectal Cancer",[29,643,644,645,646,647],"Radiosurgery","Metabolomics","Radiomics","Multi-omics","Molecular subtypes","2024-11-14",{"date":650,"type":34},"2024-11-18",{"date":652,"type":34},"2022-12-01",{"date":654,"type":21},"2037-12-31",{"name":656,"class":73},"Institut Investigacio Sanitaria Pere Virgili",{"id":658,"slug":659,"hasResults":12,"nctId":660,"briefTitle":661,"officialTitle":662,"acronym":4,"eligibilityCriteria":663,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":664,"targetDuration":4,"studyType":209,"phases":4,"briefSummary":666,"conditions":667,"keywords":669,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":672,"lastUpdatePostDateStruct":673,"startDateStruct":675,"completionDateStruct":677,"leadSponsor":678,"locationsCount":417},"100531638","predicting-tumor-metastasis-by-employing-a-target-organprimary-lesion-fusion-radiomics-model-100531638","NCT06202404","Predicting Tumor Metastasis by Employing a Target Organ\u002FPrimary Lesion Fusion Radiomics Model","Predicting Tumor Metastasis by Employing a Target Organ\u002FPrimary Lesion Fusion Radiomics Model: a Prospective Observational Trial","Inclusion Criteria:\n\n1. ECOG performance status score 0-2;\n2. Histologically or cytologically confirmed stage III-IV NSCLC;\n3. If the baseline pathology is adenocarcinoma, driver gene testing (at least EGFR\u002FALK\u002FROS1\u002FKRAS\u002FMET) should be performed;\n4. Complete imaging data of baseline stage (contrast-enhanced MR For lung cancer, contrast-enhanced MR\u002FCT for colorectal cancer, and chest CT for breast cancer);\n5. No target organ metastasis on baseline imaging (no brain\u002Fliver\u002Flung metastasis for lung cancer\u002Fcolorectal cancer\u002Fbreast cancer, respectively);\n6. Patients received at least one systemic therapy (chemotherapy, targeted therapy, immunotherapy, etc.) and received regular follow-up;\n7. Regular follow-up during and after treatment;\n8. Life expectancy ≥6 months;\n\nExclusion Criteria:\n\n1. Patients with indeterminate pathological type;\n2. Patients without baseline imaging data before treatment;\n3. Baseline imaging examination showed that the corresponding target organ had metastasis (lung cancer\u002Fcolorectal cancer\u002Fbreast cancer corresponding to brain\u002Fliver\u002Flung metastasis);\n4. patients who cannot or refuse to receive regular imaging follow-up;\n5. Combined history of other malignant tumors;\n6. Medical examination or clinical findings or other uncontrollable conditions that the investigator considers may interfere with the results or increase the risk of treatment complications for the patient; ,\n7. Lactating or pregnant women;\n8. Receiving other long-term medications that may affect disease progression as assessed by a physician.",{"count":665,"type":21},166,"A pre-metastatic target organ\u002Fprimary lesion fusion radiomics model was developed based on the \"soil-seed\" theory to predict comman tumor metastasis in retrospective settings. To prospectively verify the performance of the target organ\u002Fprimary lesion fusion radiomics model in predicting tumor metastasis patterns (brain metastasis in lung cancer, liver metastasis in colorectal cancer, lung metastasis in breast cancer), we designed this prospective observational trial.",[29,668],"Predictive Cancer Model",[60,670,671],"radiomics","seed and soil theory","2024-02-08",{"date":674,"type":34},"2024-02-09",{"date":676,"type":34},"2024-01-01",{"date":518,"type":21},{"name":679,"class":73},"Fudan University"]